DURECT Co. (DRRX) Position Boosted by Ingalls & Snyder LLC

Ingalls & Snyder LLC boosted its position in DURECT Co. (NASDAQ:DRRX) by 33.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,601,204 shares of the specialty pharmaceutical company’s stock after buying an additional 2,174,122 shares during the period. Ingalls & Snyder LLC owned approximately 5.79% of DURECT worth $7,929,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in DRRX. Mangrove Partners raised its holdings in shares of DURECT by 274.5% during the third quarter. Mangrove Partners now owns 1,271,591 shares of the specialty pharmaceutical company’s stock valued at $2,251,000 after purchasing an additional 932,070 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in shares of DURECT by 61.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 263,476 shares of the specialty pharmaceutical company’s stock valued at $467,000 after purchasing an additional 100,200 shares during the period. Tocqueville Asset Management L.P. raised its holdings in shares of DURECT by 70.3% during the third quarter. Tocqueville Asset Management L.P. now owns 2,043,383 shares of the specialty pharmaceutical company’s stock valued at $3,617,000 after purchasing an additional 843,383 shares during the period. Asymmetry Capital Management L.P. acquired a new position in shares of DURECT during the second quarter valued at about $1,636,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of DURECT by 12.1% during the second quarter. The Manufacturers Life Insurance Company now owns 120,977 shares of the specialty pharmaceutical company’s stock valued at $189,000 after purchasing an additional 13,072 shares during the period. Institutional investors and hedge funds own 44.69% of the company’s stock.

Shares of DURECT Co. (NASDAQ:DRRX) traded up $0.03 during midday trading on Friday, hitting $1.20. 468,911 shares of the stock traded hands, compared to its average volume of 733,933. DURECT Co. has a 52-week low of $0.74 and a 52-week high of $2.17. The firm has a market capitalization of $178.26, a price-to-earnings ratio of -8.00 and a beta of 1.68. The company has a quick ratio of 1.57, a current ratio of 1.67 and a debt-to-equity ratio of 1.46.

DURECT (NASDAQ:DRRX) last announced its quarterly earnings data on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.09. The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $5.09 million. DURECT had a negative net margin of 62.57% and a negative return on equity of 419.65%. sell-side analysts forecast that DURECT Co. will post -0.14 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on DRRX shares. Laidlaw dropped their price objective on shares of DURECT from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, October 20th. ValuEngine lowered shares of DURECT from a “sell” rating to a “strong sell” rating in a report on Saturday, October 21st. Stifel Nicolaus lowered shares of DURECT from a “buy” rating to a “hold” rating in a report on Friday, October 20th. Finally, HC Wainwright reiterated a “hold” rating on shares of DURECT in a report on Thursday, November 2nd.

TRADEMARK VIOLATION NOTICE: “DURECT Co. (DRRX) Position Boosted by Ingalls & Snyder LLC” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://ledgergazette.com/2018/01/19/durect-co-drrx-position-boosted-by-ingalls-snyder-llc.html.

DURECT Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Want to see what other hedge funds are holding DRRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DURECT Co. (NASDAQ:DRRX).

Institutional Ownership by Quarter for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply